as per annexure enclosed
Awaiting price reaction for this filing.
Apollo Hospitals' Board approved audited standalone and consolidated financial results for FY25 (year ended March 31, 2025) with an unmodified opinion from Deloitte Haskins & Sells LLP. Consolidated revenue grew ~14.3% to Rs.21,794 crore and consolidated PAT jumped ~61% to Rs.1,505 crore; standalone revenue rose ~12.7% to Rs.8,202 crore and standalone PAT grew ~28.3% to Rs.1,296 crore, with EPS of Rs.100.56 (consolidated) and Rs.90.15 (standalone). A total dividend of Rs.19/share (380%) has been recommended for FY25, including a Rs.10/share final dividend subject to AGM approval. The Board also approved acquiring an existing 200-bed hospital for Rs.285 crore, re-appointed three Executive Directors (Preetha, Suneeta and Sangita Reddy) and Independent Director Som Mittal, and appointed new Secretarial Auditors. Credit ratings were reaffirmed at AA+/Stable by CRISIL and India Ratings.
Strong earnings growth, particularly on the consolidated side, and a healthy 380% dividend payout are positive for shareholders. The Rs.285 crore hospital acquisition signals continued capacity expansion, while the sharp rise in consolidated borrowings (from Rs.2,236 crore to Rs.4,417 crore non-current) is worth monitoring for leverage, even as overall qualified borrowings declined.